Last reviewed · How we verify
CHRONVAC-C®
At a glance
| Generic name | CHRONVAC-C® |
|---|---|
| Sponsor | Tripep AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects (PHASE2)
- Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHRONVAC-C® CI brief — competitive landscape report
- CHRONVAC-C® updates RSS · CI watch RSS
- Tripep AB portfolio CI